Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 March 2022 | Story Leonie Bolleurs | Photo Charl Devenish
Prof Liezel Herselman Inuagural Lecture
At the inaugural lecture were from the left: Prof Danie Vermeulen, Dean of the Faculty of Natural and Agricultural Sciences, Prof Liezel Herselman, Dr Adré Minnaar-Ontong, Senior Lecturer in the Department of Plant Sciences and Subject Head of Plant Breeding, and Dr Molapo Qhobela, Vice-Rector: Institutional Change, Strategic Partnerships and Societal Impact.

Prof Liezel Herselman, Academic Head of the Department of Plant Sciences at the University of the Free State (UFS),) delivered her inaugural lecture on the Bloemfontein Campus this week (24 March 2022). The theme of the lecture was the ongoing battle against destructive cereal killers. 

With 28 years of extensive experience as a researcher, her work focuses on marker-assisted disease resistance breeding in wheat within a South African context. When she joined the UFS in 2004, Prof Herselman decided to apply her research expertise in marker-assisted breeding to the problems faced by wheat producers in the Free State and Northern Cape. The Free State is one of the major dryland wheat production areas in South Africa, while irrigation wheat is produced along the major rivers in the Northern Cape. 

Protection against fungal diseases

Concentrating specifically on Fusarium head blight (or wheat scab) and three rust diseases – leaf rust, stem rust, and stripe rust – she has done work to provide wheat plants with ‘tools’ to protect themselves against these fungal diseases.

According to Prof Herselman, there are many genes available in different wheat genotypes and related grass species that provide excellent protection against various races of these diseases. “Some of these genes provide protection or resistance from the seedling stage, while others provide resistance at the adult plant stage. We are thus aiming to combine as many of these genes as possible into a single wheat cultivar, without compromising yield and bread-making quality.”

She says the genes are combined by making crosses between resistant and susceptible cultivars or lines. Conventionally, through a time-consuming process, the incorporation of these genes is tested in the greenhouse and field by infecting plants with the disease to see which plants are resistant and which are not.

They can, however, follow the transfer of these genes to newly developed lines by applying molecular markers. Prof Herselman explains: “A molecular marker is a genomic fragment linked to the gene, which we can follow in the offspring we create from the crosses using different DNA techniques in the laboratory. This enables us to select new wheat lines that contain the highest number of resistance genes. The identified best lines are then used in further crosses and/or released as pre-breeding lines to commercial wheat breeding companies.”

Impact on food security

Her research has an impact on society by providing food security to both commercial and small-scale producers, as well as the end users of wheat (people buying bread and other wheat products). As researcher, it is also important for her to send out students to the workplace who can continue with this task in future.

Prof Herselman believes that when cultivars with fungal-disease tolerance or resistance are released and used by producers, it not only reduces the cost of spraying against diseases, but also increases yields by protecting the crop against fungal diseases. “We live in a world where the population is increasing daily, but land available for agriculture is not increasing and some areas are even lost due to urban development. Increasing yield in available production areas will thus have a positive impact on food security,” she says.

Besides contributing to the country’s food security, she takes pleasure in every aspect of her work. Although she misses the hands-on part of the work as academic head of the department and getting her hands dirty, she still enjoys managing the different research projects (from the conceptualisation phase to data analysis and publishing of results). The part she loves the most is to see the growth in her postgraduate students – from the moment they enter the laboratory for the first time until the day they walk out of the laboratory with their degrees. 

“It adds purpose to my life knowing that I have made a difference in a student’s life and equipped him or her with the necessary tools to be successful in the marketplace. Being able to share your knowledge is a gift, but with that gift comes a lot of responsibility as well. I am, however, up for the challenge,” concludes Prof Herselman. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept